Actively Recruiting

Age: 18Years - 80Years
All Genders
ID07375225

Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy - The ALINET Registry

Led by Federico II University · Updated on 2026-01-29

1500

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating how well patients with hypercholesterolaemia in Italy stick to and respond to treatment with alirocumab 300 mg. This observational study focuses on patients receiving this medication in real-life settings to better understand adherence, persistence, and treatment effectiveness over time. Participants in this study are patients already taking alirocumab 300 mg injections. The study observes their treatment without assigning interventions, tracking outcomes over periods of 6, 12, 24, and 36 months to assess adherence, persistence, and efficacy of the medication. During the study, researchers will collect data at regular intervals up to 36 months to evaluate treatment adherence, persistence, efficacy, and safety. Participants' ongoing treatment will be monitored through clinical assessments and records, with no additional treatment required as part of the study. The total participation time can last up to three years.

CONDITIONS

Brief Title

Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients under alirocumab 300mg treatment.
Not Eligible

You will not qualify if you...

  • Age less than 18 years or greater than 80 years.
  • Patients who refuse to participate and to sign informed consent.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Up to 36 months

Participants receive Alirocumab 300 mg injections as part of their treatment for hyperlipidaemia.

Visits may occur at 6, 12, 24, and 36 months to assess adherence, persistence, efficacy, and safety.

Trial Site Locations

Total: 1 location

1

Federico II University of Naples, Department of Advanced Biomedical Sciences

Naples, Napoli, Italy, 80131

Actively Recruiting

Loading map...

Research Team

P

Pasquale Perrone Filardi

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

A Phase 1 Open-label, Multicenter Trial Evaluating Safety an...

Cardiovascular

Actively Recruiting

18 locations

A Randomized, Double-Blind, Placebo-Controlled Study to Asse...

Hypercholesterolaemia

Actively Recruiting

1 location

Latin America Lipid Optimization After Acute Event in Patien...

Hypercholesterolaemia

Actively Recruiting

11 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here